SSGJ-706
SSGJ-706 is an experimental bispecific antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials for non-small-cell lung cancer, aimed at PD-1 and PD-L1.
Overview
SSGJ-706 is a bispecific antibody developed by Shenyang Sunshine Pharmaceutical. Its targets are PD-1 and PD-L1. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT07171606, plans to enrol 240 participants with primary completion expected 2026-08-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"SSGJ-706" OR ABSTRACT:"SSGJ-706") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SSGJ-706, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentT3011
Shares PD-L1, PD-1, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentHB0036
Shares PD-L1, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentTQB2450
Shares PD-L1, PD-1, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentRilvegostomig
Shares PD-1, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentPF-08046054
Shares PD-L1, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentAZD7789
Shares PD-1, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentSasanlimab
- TreatmentSSGJ-705
Shares PD-1 and the tags pipeline, ctgov-ingest.